MIC Test Strip for antimicrobial susceptibility testing

Similar documents
Discussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category

Expert rules in antimicrobial susceptibility testing: State of the art

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator

Both adult and pediatric* 24 (46% of 52 members) Region: New England 51 (48% of 107 members) 45 (52% of 87 members) 29 (47% of 62 members)

University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology

Drug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD

What is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden

HUSRES Annual Report 2009 Martti Vaara

2019 PHP PRIMARY CARE INCENTIVE

This material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.

Screening and detection of carbapenemases

Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)

PK/PD degli antibiotici utilizzati nella sepsi

EUCAST Frequently Asked Questions. by author. Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator

Disclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program

ESCMID Online Lecture Library. by author

Update on CLSI and EUCAST

Report on susceptibility of Salmonella serotypes in Belgium Vicky Jasson

Phenotypic detection of ESBLs and carbapenemases

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and

Insert for Kit 98006/98010/ KPC/Metallo-B-Lactamase Confirm Kit KPC+MBL detection Kit KPC/MBL and OXA-48 Confirm Kit REVISION: DBV0034J

hydrophila strain ACCEPTED *Corresponding author. Department of Bacteriology, National Center for Epidemiology, 1097

Expert rules. for Gram-negatives

β-lactamase inhibitors

Controversial Issues in Susceptibility Testing: Point/Counterpoint. April N. Abbott, PhD D(ABMM) Romney M. Humphries, PhD D(ABMM)

Antibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Disclosures. Objectives 3/6/2016. Achaogen: Allergan:

This letter authorises the extended use of the following guidance until 1st December 2018:

HARDYDISK ANTIMICROBIAL SENSITIVITY TEST (AST)

Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.

Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia

CEFACLOR Non Formulary 5.1 Antibacterial drugs->5.1.2 Cephalosporins, carbapenems, and other beta-lactams-> Cephalosporins

SUPPLEMENTAL TESTING. Tan Thean Yen

July 2011 IN THIS ISSUE:

Carbapenems and Enterobacteriaceae

ADULT ANTIMICROBIAL DOSING TOOL (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017)

Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan

In Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria

Author: Souha Kanj Andrew Whitelaw Michael J. Dowzicky. To appear in: International Journal of Antimicrobial Agents

Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains

Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae

Detecting CRE. what does one need to do?

Panel discussion-aidc 2017 Rapport with the microbiology lab-how it helps your patient

Sep Oct Nov Dec Total

Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents

Clinical Microbiology Newsletter

Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia

FÜR RISIKOBEWERTUNG BUNDESINSTITUT. Proposal for a common Staphylococci panel design. Andreas Schroeter, BfR Antonio Battisti, ISS Dik Mevius, CIDC

Other β-lactam. A. Carbapenems:

HOW BUGS COMBAT DRUGS: ANTIMICROBIAL RESISTANCE MECHANISMS IN THE MODERN ERA. Romney Humphries, PhD D(ABMM)

Dry injection list 1-Ceftriaxone 1000 mg & Sulbactam 500 mg Inj. 2-Ceftriaxone 500 mg & Sulbactam 250 mg Inj.

Chapter 5 ~ Infections

Methodological and interpretative problems in antimicrobial susceptiblity tests of P. aeruginosa

Overcoming the PosESBLities of Enterobacteriaceae Resistance

Rapid identification of emerging resistance in Gram negatives. Prof. Patrice Nordmann

Academic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE

Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED

MONTEFIORE MEDICAL CENTER

Handbook of Antimicrobial Therapy

Methods for colistin testing What works and what does not? Erika Matuschek, Ph D EUCAST Development Laboratory, EDL

Prevalence of Carbapenem Resistance in Gram Negative Bacilli Isolates and Their Antimicrobial Susceptibility Pattern

CANDIDA SPECIES ARE THE

Antibiotic Dosing in the Elderly

AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac

Activity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates

Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011

ST11 KPC-2 Klebsiella pneumoniae detected in Taiwan

Aerobic bacterial Profile of Diabetic Foot Ulcers and their Antibiotic Sensitivity Pattern

Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)

Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?

Adenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes

Detecting carbapenemases in Enterobacteriaceae

Why some tests are no longer recommended

Antibiotic Classification Antibiotic Classification and Modes of Action

New Mechanisms of Antimicrobial Resistance and Methods for Carbapenemase Detection

Antibiotics to treat multi-drug-resistant bacterial infections

NEW DEVELOPMENTS AND CHALLENGING CASES IN HOSPITAL INFECTIOUS DISEASES

Incidence of metallo beta lactamase producing Pseudomonas aeruginosa in ICU patients

Canadian Nosocomial Infection Surveillance Program 2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING PEDIATRIC CARDIAC SURGERY

Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections

XERAVATM (eravacycline): A Novel Fluorocycline Antibacterial

CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE

First description of KPC-2-producing Pseudomonas putida in Brazil. Anna C. S. Almeida, Marinalda A. Vilela*, Felipe L.S. Cavalcanti, Willames M.B.S.

New Antimicrobials: Now and In the Future

PRESENCE OF ACINETOBACTER BAUMANNII IN NATURAL ENVIRONMENT IN CROATIA

ISSN X (Print) Research Article

Clinical Management of Infections Caused by Enterobacteriaceae that Express Extended- Spectrum β-lactamase and AmpC Enzymes

ECFSPR ENCOUNTER VARIABLES (vs 1.1)

EXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? Prof Patrick Honoré,MD, PhD, Intensivist-Nephrologist

Update zu EUCAST 2012 Cornelia Lass-Flörl

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria

Report generated from BNF provided by FormularyComplete ( Accessed TA Number. Title Formulary Status Section

ALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.

Urinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014

Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France

Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH

Transcription:

for antimicrobial susceptibility testing Liofilchem Liofilchem Quantitative assay for determining the Minimum Inhibitory Concentration (M.I.C.) is a quantitative assay for determining the Minimum Inhibitory Concentration (M.I.C.) of antimicrobial agents against microorganisms and for detecting the resistance mechanisms. are porous strips with special features (International Patent) that are impregnated with a predefined concentration gradient of antibiotic, across 15 two-fold dilutions of a conventional M.I.C. method. On one side of the strip is indicated a M.I.C. scale in μg/ml and a code that identify the antimicrobial agent. For ESBL, MBL, GRD, AmpC and KPC detection, the double-sided gradient carries the appropriate diagnostic reagents. are available in a large variety of configurations. Each configuration is available in packages of 10, 30 and 100 tests. Mixed culture on Chromatic MH Meropenem 0.002-32 μg/ml Staphylococcus aureus ATCC 29213 Tigecycline 0.016-256 μg/ml M.I.C. = 0.19 μg/ml method principle When the is applied onto an inoculated agar surface, the preformed exponential gradient of antimicrobial agent is immediately transferred to the agar matrix. After 18 hours incubation or longer, a symmetrical inhibition ellipse centered along the strip is formed. The MIC is read directly from the scale in terms of μg/ml at the point where the edge of the inhibition ellipse intersects the strip. Other growth/inhibition patterns may also be seen for resistance detection methods. Staphylococcus aureus Vancomycin / Teicoplanin GRD+ Klebsiella pneumoniae Ertapenem / Ert. +Phenylboronic acid KPC + BIBLIOGRAPHY CLSI M100-S27, 2017. Performance Standards for Antimicrobial Susceptibility Testing. CLSI M7-A10, 2015. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. CLSI M11-A8 Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. CLSI M11-S1 Performance Standards for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. CLSI M27-A3. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard - Third Edition. CLSI M27-S4. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth Informational supplement. EUCAST. Breakpoint tables Please for interpretation contact info@ewcdiagnostics.com of MICs and zone or call diameters +31 (0)6 15606050 Version 7.1, March 2017.

for ANTIMICROBIAL susceptibility testing AMIKACIN 0.016-256 AK 920181 92018 920180 AMOXICILLIN 0.016-256 AML AMOXICILLIN*-CLAVULANIC ACID (2/1) CLSI recommended AMOXICILLIN*-CLAVULANIC ACID (2 μg/ml) EUCAST recommended 0.016-256* AUG 0.016-256* AMC AMPICILLIN 0.016-256 AMP AMPICILLIN*-SULBACTAM (2/1) CLSI recommended AMPICILLIN*-SULBACTAM (4 μg/ml) EUCAST recommended 0.016-256* AMS 0.016-256* SAM AZITHROMYCIN 0.016-256 AZM AZTREONAM 0.016-256 ATM AZTREONAM 0.064-1024 ATM BACITRACIN 0.016-256 BA CEFACLOR 0.016-256 CEC CEFAZOLIN 0.016-256 KZ CEFEPIME 0.016-256 FEP CEFIXIME 0.016-256 CFM CEFOPERAZONE*-SULBACTAM (2/1) 0.016-256* CPS CEFOTAXIME 0.002-32 CTX CEFOTAXIME 0.016-256 CTX CEFOTETAN 0.016-256 CTT CEFOXITIN 0.016-256 FOX CEFPIROME 0.016-256 CR CEFPODOXIME 0.016-256 PX CEFTAROLINE 0.002-32 CPT CEFTAROLINE 0.016-256 CPT CEFTAZIDIME (FDA cleared) 0.016-256 CAZ CEFTAZIDIME*-AVIBACTAM 0.016-256* CZA CEFTIBUTEN 0.002-32 CTB CEFTIZOXIME 0.016-256 CZX CEFTOBIPROLE 0.002-32 BPR CEFTOLOZANE*-TAZOBACTAM (FDA cleared) 0.016-256* C/T 920211 92021 920210 920241 92024 920240 921801 92180 921800 920031 92003 920030 920271 92027 920270 921811 92181 921810 920301 92030 920300 920331 92033 920330 921731 92173 921730 920191 92019 920190 920361 92036 920360 921741 92174 921740 921261 92126 921260 920601 92060 920600 920231 92023 920230 920071 92007 920070 920061 92006 920060 920201 92020 920200 920661 92066 920660 920081 92008 920080 920051 92005 920050 920561 92056 920560 920491 92049 920490 921381 92138 921380 921391 92139 921390 920581 92058 920580 920161 92016 920160 921401 92140 921400 921461 92146 921460

for ANTIMICROBIAL susceptibility testing CEFTRIAXONE 0.016-256 CRO 920421 92042 920420 CEFTRIAXONE 0.002-32 CRO CEFUROXIME 0.016-256 CXM CEPHALOTHIN 0.016-256 KF CHLORAMPHENICOL 0.016-256 C CIPROFLOXACIN 0.002-32 CIP CLARITHROMYCIN 0.016-256 CLR CLINDAMYCIN (FDA cleared) 0.016-256 CD CLOXACILLIN 0.016-256 CX 920431 92043 920430 921291 92129 921290 920391 92039 920390 920751 92075 920750 920451 92045 920450 920481 92048 920480 920721 92072 920720 920441 92044 920440 Sensitest COLISTIN SENSITEST NEW! 0.25-16 CS 16 tests 75001 Sensitest SENSITEST COLISTIN NEW! 0.25-16 CS 16 tests 75001 DALBAVANCIN (FDA cleared) 0.002-32 DAL DAPTOMYCIN (Includes Ca 2+ ) 0.016-256 DAP DELAFLOXACIN (FDA cleared) 0.002-32 DLX DORIPENEM 0.002-32 DOR DOXYCYCLINE 0.016-256 DXT ENROFLOXACIN 0.002-32 ENR ERTAPENEM 0.002-32 ETP ERYTHROMYCIN 0.016-256 E FLORFENICOL 0.016-256 FFC FOSFOMYCIN (Includes Glucose-6-Phosphate) 0.016-256 FOS FOSFOMYCIN (Includes Glucose-6-Phosphate) 0.064-1024 FOS FUSIDIC ACID 0.016-256 FU GATIFLOXACIN 0.002-32 GAT GEMIFLOXACIN 0.002-32 GEM GENTAMICIN 0.016-256 CN GENTAMICIN 0.064-1024 CN IMIPENEM 0.002-32 IMI KANAMYCIN 0.016-256 K LEVOFLOXACIN 0.002-32 LEV 921371 92137 921370 921451 92145 921450 920801 92080 920800 920401 92040 920400 921561 92156 921560 920131 92013 920130 921571 92157 921570 920511 92051 920510 920611 92061 920610 920781 92078 920780 920791 92079 920790 920021 92002 920020 920111 92011 920110 920351 92035 920350 920091 92009 920090 920101 92010 920100 920541 92054 920540 920341 92034 920340 920811 92081 920810

for ANTIMICROBIAL susceptibility testing LINEZOLID 0.016-256 LNZ 921351 92135 921350 MARBOFLOXACIN 0.002-32 MAR MECILLINAM 0.016-256 MEC MEROPENEM (FDA cleared) 0.002-32 MRP MEROPENEM 0.016-256 MRP METRONIDAZOLE 0.016-256 MTZ MOXIFLOXACIN 0.002-32 MXF MUPIROCIN 0.064-1024 MUP MINOCYCLINE 0.016-256 MN NALIDIXIC ACID 0.016-256 NA NETILMICIN 0.016-256 NET NORFLOXACIN 0.016-256 NOR NITROFURANTOIN 0.032-512 F OFLOXACIN 0.002-32 OFX OXACILLIN 0.016-256 OX PENICILLIN G 0.002-32 P PENICILLIN G 0.016-256 P PIPERACILLIN 0.016-256 PIP PIPERACILLIN*-TAZOBACTAM (4 μg/ml) 0.016-256* TZP POLYMYXIN B 0.064-1024 PB QUINUPRISTIN-DALFOPRISTIN 0.002-32 QDA RIFAMPICIN 0.002-32 RD RIFAMPICIN 0.016-256 RD SPECTINOMYCIN 0.064-1024 SPC SPIRAMYCIN 0.002-32 SP STREPTOMYCIN 0.064-1024 S SULBACTAM 0.016-256 SUL SULFAMETHOXAZOLE 0.064-1024 SMX TEDIZOLID (FDA cleared) 0.002-32 TZD TEICOPLANIN 0.016-256 TEC 920621 92062 920620 920171 92017 920170 920841 92084 920840 920851 92085 920850 920871 92087 920870 920901 92090 920900 920381 92038 920380 920321 92032 920320 921321 92132 921320 920931 92093 920930 920961 92096 920960 920221 92022 920220 920991 92099 920990 920151 92015 920150 921031 92103 921030 921021 92102 921020 921051 92105 921050 921081 92108 921080 920041 92004 920040 920261 92026 920260 920011 92001 920010 920251 92025 920250 920141 92014 920140 920461 92046 920460 921111 92111 921110 920281 92028 920280 920311 92031 920310 921361 92136 921360 920121 92012 920120

for ANTIMICROBIAL susceptibility testing TELAVANCIN 0.002-32 TLV 920521 92052 920520 TELAVANCIN (FDA cleared) 0.016-256 TLV TEMOCILLIN 0.064-1024 TMO TETRACYCLINE 0.016-256 TE TIAMULIN 0.002-32 TIA TICARCILLIN*-CLAVULANIC ACID (2 μg/ml) 0.016-256* TTC TIGECYCLINE 0.016-256 TGC TILMICOSIN 0.002-32 TIL TOBRAMYCIN 0.016-256 TOB TOBRAMYCIN 0.064-1024 TOB TRIMETHOPRIM 0.002-32 TM TRIMETHOPRIM*-SULFAMETHOXAZOLE (1/19) 0.002-32* SXT VANCOMYCIN (FDA cleared) 0.016-256 VA for ANTIFUNGAL susceptibility testing 920531 92053 920530 920291 92029 920290 921141 92114 921140 922001 92200 922000 921171 92117 921170 921441 92144 921440 922011 92201 922010 921211 92121 921210 921201 92120 921200 920371 92037 920370 921231 92123 921230 920571 92057 920570 AMPHOTERICIN B 0.002-32 AMB 921531 92153 921530 ANIDULAFUNGIN 0.002-32 AND CASPOFUNGIN 0.002-32 CAS FLUCONAZOLE 0.016-256 FLU FLUCYTOSINE 0.002-32 FC ISAVUCONAZOLE 0.002-32 IVU ITRACONAZOLE 0.002-32 ITC KETOCONAZOLE 0.002-32 KE MICAFUNGIN 0.002-32 MYC POSACONAZOLE 0.002-32 POS VORICONAZOLE 0.002-32 VO for ANTIMYCOBACTERIAL susceptibility testing 921551 92155 921550 921541 92154 921540 921471 92147 921470 921491 92149 921490 921841 92184 921840 921481 92148 921480 921511 92151 921510 921821 92182 921820 921521 92152 921520 921501 92150 921500 ETHAMBUTOL 0.016-256 EB 921701 92170 921700 ETHIONAMIDE 0.016-256 ET ISONIAZIDE 0.016-256 IZ 921721 92172 921720 921711 92171 921710

ESBL for confirmation of Extended Spectrum Beta-Lactamase CEFEPIME/CEFEPIME+CLAVULANIC ACID (4 μg/ml) 0.25-16 / 0.064-4 FEP/FEL 921611 92161 921610 CEFOTAXIME/CEFOTAXIME+CLAVULANIC ACID (4 μg/ml) 0.25-16 / 0.016-1 CTX/CTL CEFTAZIDIME/CEFTAZIDIME+CLAVULANIC ACID (4 μg/ml) 0.5-32 / 0.064-4 CAZ/CAL for KPC detection 921601 92160 921600 921591 92159 921590 921671 MEROPENEM / MEROPENEM + PHENYLBORONIC ACID 0.125-8 / 0.032-2 MRP/MBO 92167 921670 921681 ERTAPENEM / ERTAPENEM + PHENYLBORONIC ACID 0.125-8 / 0.032-2 ETP/EBO 92168 921680 MBL for detection of Metallo Beta-Lactamase IMIPENEM / IMIPENEM + EDTA 4-256 / 1-64 IMI/IMD 921621 92162 921620 IMIPENEM / IMIPENEM + EDTA 0.125-8 / 0.032-2 IMI/IMD MEROPENEM / MEROPENEM + EDTA 0.125-8 / 0.032-2 MRP/MRD GRD for detection of Glycopeptide Resistance 921661 92166 921660 921651 92165 921650 VANCOMYCIN / TEICOPLANIN 0.5-32 / 0.5-32 VA/TEC 921631 92163 921630 for AmpC detection CEFOTETAN / CEFOTETAN+CLOXACILLIN 0.5-32 / 0.5-32 CTT/CXT 921641 92164 921640 ERTAPENEM / ERTAPENEM + CLOXACILLIN 0.125-8 / 0.032-2 ETP/ECX 921691 92169 921690 MTS Synergy Application System (International Patent) Description Packaging Ref. MTS Synergy Applicator Platform 1 unit 96860 MTS Synergy Delivery Tool 10 disposable applicators 96870 Accessories Description Packaging Ref. DEN-1B McFarland densitometer with built-in adapter for 18 mm tubes A-16 Adapter for 16 mm tubes CKG18 calibration kit for DEN-1, for 18mm glass tubes CKG16 calibration kit for DEN-1, for 16mm glass tubes Storage Tube with Desiccant 10 tubes 96719 McFarland Standard Set 0.5-1.0-2.0-3.0-4.0 5 tubes 80405 0.5 McFarland 1 tube 80400 1 McFarland 1 tube 80401 2 McFarland 1 tube 80402 96881 96882 96883 96884

Ready to use culture media DESCRIPTION FORMAT PACKAGING REF. MUELLER HINTON AGAR II for antimicrobial susceptibility testing of non-fastidious organisms. MUELLER HINTON AGAR II + SHEEP BLOOD 5% for antimicrobial susceptibility testing of fastidious organisms. MUELLER HINTON FASTIDIOUS AGAR (Horse blood 5% + 20 mg/l β-nad) EUCAST recommended: for antimicrobial susceptibility testing of Streptococcus spp., Haemophilus spp., and some other fastidious organisms. MUELLER HINTON AGAR II + 2% NaCl for antimicrobial susceptibility testing of staphylococci with Oxacillin. CHROMATIC MH Chromogenic medium for the preliminary identification and susceptibility testing of bacteria directly from clinical and environmental specimens. BRUCELLA BLOOD AGAR with HEMIN AND VITAMIN K1 for antimicrobial susceptibility testing of anaerobic bacteria. SCHADLER K AGAR (SHEEP BLOOD 5%) for antimicrobial susceptibility testing of anaerobic bacteria. HAEMOPHILUS TEST AGAR for Haemophilus spp. susceptibility testing. MIDDLEBROOK 7H11 AGAR for antimicrobial susceptibility testing of mycobacteria. R.P.M.I. AGAR (2% glucose + MOPS) for antifungal susceptibility testing. 10031 10231 10131 11231 10132 11132 11206 11618 10246 10245 11065 10080 10416 11509 10233 E. coli ATCC 25922 SXT 0.002-32 μg/ml M.I.C. = 0.094 μg/ml S. pneumoniae ATCC 49619 CRO 0.016-256 μg/ml M.I.C. = 0.064 μg/ml S. aureus ATCC 29213 FOX 0.016-256 μg/ml M.I.C. = 1.5 μg/ml S. pneumoniae ATCC 49619 E 0.016-256 μg/ml M.I.C. = 0.032 μg/ml C. krusei ATCC 6258 POS 0.002-32 μg/ml M.I.C. = 0.094 μg/ml S. aureus ATCC 29213 FU 0.016-256 μg/ml M.I.C. = 0.50 μg/ml C. krusei VO 0.002-32 μg/ml M.I.C. = 0.25 μg/ml P. aeruginosa ATCC 27853 TZP 0.016-256 μg/ml M.I.C. = 8 μg/ml S. maltophilia ATCC 13636 IMI/IMD 4-256/1-64 μg/ml MBL+ E. coli DSM 22311 CTX/CTL 0.25-16/0.016-1 μg/ml ESBL+ E. coli CAZ/CAL 0.5-32/0.064-4 μg/ml ESBL+ K. pneumoniae ATCC BAA-1144 CTT/CXT 0.5-32/0.5-32 μg/ml AmpC+